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Dselection and channeling biases. Because ‘‘roll-in’’ cases
were not excluded, the outcomes reflect the effect of a
learning curve. During the enrollment phase of the study,
considerable emphasis was placed on procedural training
and the sharing of best practices. Nonetheless, the possibil-
ity of performance bias could not be excluded. The clinical
endpoints were objectively defined a priori, and the out-
comes were independently determined by a clinical events
committee and an echocardiographic core laboratory.
Hence, the detection and measurement biases were miti-
gated but not eliminated. However compelling the data
appear to be at this interim analysis, the number of patients
followed up out to 3 years was small; hence, our findings
should be considered preliminary.CONCLUSIONS
The results of the TRITON trial have confirmed the
safety and efficacy of RDAVR using the Edwards Intuity
Valve System. At 3 years, the Intuity valve was associated
with a low mean transvalvular gradient and significant LV
mass regression. Moreover, compared with standard surgi-
cal bioprostheses, the Edwards Intuity might be associated
with larger EOAs in smaller valve sizes, a lower risk of
PPM owing to the structural valve design, and a low rate
of significant postoperative PVL. These hemodynamic ben-
efits were accompanied by significant improvements in pa-
tient functional status.
The authors thank Jill Trekell and Bruce Van Deman of Medical
and Clinical Affairs at Edwards Lifesciences, LLC, for their assis-
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1. Head SJ, Mokhles MM, Osnabrugge RL, Pibarot P, Mack MJ, Takkenberg JJ,
et al. The impact of prosthesis-patient mismatch on long-term survival after
aortic valve replacement: a systematic review and meta-analysis of 34 observa-
tional studies comprising 27 186 patients with 133 141 patient-years. Eur Heart
J. 2012;33:1518-29.
2. Bleiziffer S, Eichinger WB, Hettich I, Ruzicka D, Wottke M, Bauernschmitt R,
et al. Impact of patient-prosthesis mismatch on exercise capacity in patients after
bioprosthetic aortic valve replacement. Heart. 2008;94:637-41.
3. Mohty D, Dumesnil JG, Echahidi N, Mathieu P, Dagenais F, Voisine P, et al.
Impact of prosthesis-patient mismatch on long-term survival after aortic valve
replacement: influence of age, obesity, and left ventricular dysfunction. J Am
Coll Cardiol. 2009;53:39-47.
4. Rahimtoola SH. The problem of valve prosthesis-patient mismatch. Circulation.
1978;58:20-4.
5. Ruel M, Al-Faleh H, Kulik A, Chan KL, Mesana TG, Burwash IG. Prosthesis-pa-
tient mismatch after aortic valve replacement predominantly affects patients with
preexisting left ventricular dysfunction: effect on survival, freedom from heart
failure, and left ventricular mass regression. J Thorac Cardiovasc Surg. 2006;
131:1036-44.
6. Tasca G, Brunelli F, Cirillo M, DallaTombaM,Mhagna Z, Troise G, et al. Impact
of valve prosthesis-patient mismatch on left ventricular mass regression
following aortic valve replacement. Ann Thorac Surg. 2005;79:505-10.
7. Borger MA, Dohmen P, Misfeld M, Mohr FW. Current trends in aortic valve
replacement: development of the rapid deployment Edwards Intuity valve sys-
tem. Exp Rev Med Devices. 2013;10:461-70.2860 The Journal of Thoracic and Cardiovascular Sur8. Folliguet TA, Laborde F, Zannis K, Ghorayeb G, Haverich A, Shrestha M. Su-
tureless Perceval aortic valve replacement: results of two European centers.
Ann Thorac Surg. 2012;93:1483-8.
9. Martens S, Sadowski J, Eckstein FS, Bartus K, Kapelak B, Sievers HH, et al.
Clinical experience with the ATS 3f Enable(R) sutureless bioprosthesis. Eur J
Cardiothorac Surg. 2011;40:749-55.
10. Kocher AA, Laufer G, Haverich A, ShresthaM,Walther T, MisfeldM, et al. One-
year outcomes of the Surgical Treatment of Aortic Stenosis With a Next Gener-
ation Surgical Aortic Valve (TRITON) trial: a prospective multicenter study of
rapid-deployment aortic valve replacement with the Edwards Intuity Valve Sys-
tem. J Thorac Cardiovasc Surg. 2013;145:110-5; discussion 115-6.
11. Clavel MA,Webb JG, Pibarot P, Altwegg L, Dumont E, Thompson C, et al. Com-
parison of the hemodynamic performance of percutaneous and surgical bio-
prostheses for the treatment of severe aortic stenosis. J Am Coll Cardiol. 2009;
53:1883-91.
12. Pibarot P, Dumesnil JG. Prosthetic heart valves: selection of the optimal pros-
thesis and long-term management. Circulation. 2009;119:1034-48.
13. Beckmann A, Funkat AK, Lewandowski J, Frie M, Schiller W, Hekmat K, et al.
Cardiac surgery in Germany during 2012: a report on behalf of the German Society
for Thoracic and Cardiovascular Surgery. Thorac Cardiovasc Surg. 2014;62:5-17.
14. McClure RS, Narayanasamy N, Wiegerinck E, Lipsitz S, Maloney A, Byrne JG,
et al. Late outcomes for aortic valve replacement with the Carpentier-Edwards
pericardial bioprosthesis: up to 17-year follow-up in 1,000 patients. Ann Thorac
Surg. 2010;89:1410-6.
15. Forcillo J, Pellerin M, Perrault LP, Cartier R, Bouchard D, Demers P, et al. Car-
pentier-Edwards pericardial valve in the aortic position: 25-years experience.
Ann Thorac Surg. 2013;96:486-93.
16. Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP,
et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommenda-
tions for clinical practice. J Am Soc Echocardiogr. 2009;22:1-23; quiz 101-2.
17. Hahn RT, Pibarot P, Stewart WJ, Weissman NJ, Gopalakrishnan D, Keane MG,
et al. Comparison of transcatheter and surgical aortic valve replacement in severe
aortic stenosis: a longitudinal study of echocardiography parameters in cohort A
of the PARTNER trial (placement of aortic transcatheter valves). J Am Coll Car-
diol. 2013;61:2514-21.
18. Pibarot P, Dumesnil JG. Hemodynamic and clinical impact of prosthesis-patient
mismatch in the aortic valve position and its prevention. J Am Coll Cardiol. 2000;
36:1131-41.
19. Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR, et al.
Two-year outcomes after transcatheter or surgical aortic-valve replacement. N
Engl J Med. 2012;366:1686-95.Discussion
Dr Y. Joseph Woo (Stanford, Calif). My disclosure is that last
year at Penn, I was the principal investigator for the Intuity valve
trial and had the opportunity to implant both first- and second-gen-
eration devices.
Dr Wahlers, I congratulate you and your co-investigators on
your excellent presentation, outstanding results, and pioneering
leadership in conveying innovative technologies into clinical
practice.
With this presentation and the report by Kocher and Borger,10
the TRITON team has demonstrated high procedural success,
shortened crossclamp and bypass times, enhanced minimally
invasive approaches, low paravalvular regurgitation rates,
excellent midterm clinical outcomes, LV mass regression, and
persistent single-digit mean gradients, with particular benefit in
the smaller annulus. I have 4 questions.
First, your hypothesis for the mechanism of generating a larger
EOA in the smaller annulus is that the balloon expandable stent
mechanically widens the LV outflow tract. Did you observe an
elevated incidence of transient conduction abnormalities or me-
chanical interference with mitral valve anterior leaflet mobility
or function?gery c December 2014
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DDr Wahlers. Dr Woo, thank you very much for the question.
I think the balloon expansion widens the outflow tract a little bit
but not permanently. We have not seen any dysfunctions leading to
pacemaker implantation, reflected by the pacemaker implant rate,
which was low or comparable to that with other prostheses.
Also, no interferencewith themitral valve anterior leaflet has been
reported to date. That might be also related to the, let us say, accept-
able height of the prosthesis. Thevalve is not sodeep sitting in theLV
outflow tract; thus, we have concluded that it does not interfere.
DrWoo.Thank you. Second, the size 19 Intuity valve compared
well with the reference echocardiographic data of the EOAs of
various other bioprostheses. However, when you study the rest
of the tabular data and you compare the Intuity valve against the
Magna, on which the Intuity was based, the data you presented re-
vealed that the size 23 and 25 Intuity EOAs, even with the
expanded LV outflow tract, were actually smaller than the corre-
sponding Magna EOAs. How would you reconcile this?
Dr Wahlers. Well, this is difficult to explain. What I can tell
you from the raw data is that we did not have all the values assessed
in every individual patient at all follow-up points. That might have
influenced the small sizes of the numbers, and we will have to wait
for larger patient numbers to correct for that.
DrWoo. Thank you. Third, based on either perception or direct
experience, would you be kind enough to offer any comparisons
between this device and another sutureless aortic bioprosthesis
widely available in Europe?
Dr Wahlers. That is a good point. I think the advantage of this
valve is that one has a conventional valve mounted on a stent, and
all other valves have new designs. That is the first point.
So, the new designs have to prove they will have the same dura-
bility as that of the Magna design, which has already been proved.
That addresses the first point.
The second point is that with the balloon dilatation of the LV
outflow tract, I think the fitting will be better in general compared
with that of the other valves available and, therefore, more
reproducible.The Journal of Thoracic and CarDr Woo. Thank you. Finally, given relative differences in the
magnitude of the procedure and device costs among transcatheter
aortic valve replacement, RDAVR, and standard bioprostheses,
where do you envision the ultimate niche for rapid deployment
or sutureless AVR?
Dr Wahlers. Well, this is a difficult question to answer. If one
can purchase this type of prosthesis for the same price as that of a
stented prosthesis, I would totally switch in the small sizes. So, it is
a question of the policy of the company regarding where to place
the costs.
It is really an advantage to use this valve in patients in whom
one wants to have a short clamp time. So, for redo procedures,
combined procedures in which one has impaired LV function,
and, perhaps, also in the small sizes, such as I mentioned, 19 or
21 mm, the valve might provide advantages with regard to the pa-
rameters I showed.
Dr Woo. Thank you again for your leadership in advancing the
field.
Dr Wahlers. Thank you very much for your kindness.
Dr Hans-Joachim Sch€afers (Homburg/Saar, Germany). One
quick question—you said in your presentation that the pacemaker
rate was 6%, which is somewhat greater than that after conven-
tional AVR, and valve related was 3%. How did you differentiate
between the 2?
Dr Wahlers. Let me explain the data. If the patient had pre-
existent disturbances, such bundle branch block, this led more
easily to a pacemaker being needed postoperatively. All other
pacemaker implantations were counted as directly related to
the valve implantation in patients who had not had these prob-
lems preoperatively.
We wanted to be very exact in our analysis, and if you
compare the percentage 6.9% for early pacemaker implantation,
this compares fairly well with the published data for pacemaker
rates in patients with a stented bioprosthesis. So, it is not
higher, which perhaps was suspected due to the stent design
before.diovascular Surgery c Volume 148, Number 6 2861
